Colestipol — Discount Pricing

Other medications in Heart & Cardiovascular

• Colestipol (Lipid)
• Dapagliflozin (HF)
• Digoxin
• Diltiazem
• Dobutamine
• Dronedarone
• Empagliflozin (HF)
• Enalapril

What Colestipol is approved for (FDA label)

Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines).

Source: Read the full FDA label on DailyMed. Label effective date: June 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Colestipol (FDA label)

Gastrointestinal The most common adverse reactions are confined to the gastrointestinal tract. To achieve minimal GI disturbance with an optimal LDL-C lowering effect, a gradual increase of dosage starting with 2 grams, once or twice daily is recommended. Constipation is the major single complaint and at times is severe. Most instances of constipation are mild, transient, and controlled with standard treatment. Increased fluid intake and inclusion of additional dietary fiber should be the first step; a stool softener may be added if needed. Some patients require decreased dosage or discontinuation of therapy. Hemorrhoids may be aggravated.

Source: FDA prescribing information (DailyMed). Set ID: 515f9b07-7c03-0a2b-e063-6394a90a617d. SPL document ID: 515f9c9d-c91c-f5ac-e063-6294a90a2f3d. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Colestipol (FDA label)

Colestipol hydrochloride tablets are contraindicated in those individuals who have shown hypersensitivity to any of their components.

Source: FDA prescribing information (DailyMed). Set ID: 515f9b07-7c03-0a2b-e063-6394a90a617d. SPL document ID: 515f9c9d-c91c-f5ac-e063-6294a90a2f3d. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Colestipol (FDA label)

Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids. In vitro studies have indicated that colestipol hydrochloride binds a number of drugs. Therefore, colestipol hydrochloride tablets may delay or reduce the absorption of concomitant oral medication. The interval between the administration of colestipol hydrochloride tablets and any other medication should be as long as possible. Patients should take other drugs at least one hour before or four hours after colestipol hydrochloride tablets to avoid impeding their absorption. Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.

Source: FDA prescribing information (DailyMed). Set ID: 515f9b07-7c03-0a2b-e063-6394a90a617d. SPL document ID: 515f9c9d-c91c-f5ac-e063-6294a90a2f3d. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.